On Friday Suven Life Sciences said that it has got five product patents for their drug in Europe, Hong Kong, Israel, Australia and Norway for the treatment of disorders associated with neuro-degenerative diseases.

Suven Life Science in a BSE filing said, “The grant of 1 product patent from Australia, one from Europe, one from Hong Kong, one from Israel and one from Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.”

It also added that the granted claims of the patents include the class of selective 5-HT compounds discovered by Suven.

With these new patents, Suven has a total of 21 granted patents from Australia, 16 from Hong Kong, 15 from Europe, 4 from Israel and 5 from Norway. All these granted patents are an exclusive intellectual property of Suven and has been achieved through the internal discovery research efforts.